183 related articles for article (PubMed ID: 36270254)
1. Evidence for novel cell defense mechanisms sustained by dimethyl fumarate in multiple sclerosis patients: the HuR/SOD2 cascade.
Mallucci G; Marchesi N; Campagnoli LIM; Boschi F; Fahmideh F; Fusco S; Tavazzi E; Govoni S; Bergamaschi R; Pascale A
Mult Scler Relat Disord; 2022 Dec; 68():104197. PubMed ID: 36270254
[TBL] [Abstract][Full Text] [Related]
2. Unraveling a new player in multiple sclerosis pathogenesis: The RNA-binding protein HuR.
Pistono C; Monti MC; Marchesi N; Boiocchi C; Campagnoli LIM; Morlotti D; Cuccia M; Govoni S; Montomoli C; Mallucci G; Bergamaschi R; Pascale A
Mult Scler Relat Disord; 2020 Jun; 41():102048. PubMed ID: 32200342
[TBL] [Abstract][Full Text] [Related]
3. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Wang Q; Chuikov S; Taitano S; Wu Q; Rastogi A; Tuck SJ; Corey JM; Lundy SK; Mao-Draayer Y
Int J Mol Sci; 2015 Jun; 16(6):13885-907. PubMed ID: 26090715
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
[TBL] [Abstract][Full Text] [Related]
8. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Yadav SK; Soin D; Ito K; Dhib-Jalbut S
J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
[TBL] [Abstract][Full Text] [Related]
10. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
[TBL] [Abstract][Full Text] [Related]
11. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
14. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
Mallucci G; Annovazzi P; Miante S; Torri-Clerici V; Matta M; La Gioia S; Cavarretta R; Mantero V; Costantini G; D'Ambrosio V; Zaffaroni M; Ghezzi A; Perini P; Rossi S; Bertolotto A; Rottoli MR; Rovaris M; Balgera R; Cavalla P; Montomoli C; Bergamaschi R
J Neurol; 2018 Aug; 265(8):1850-1859. PubMed ID: 29948245
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis.
Nicoletti CG; Landi D; Monteleone F; Mataluni G; Albanese M; Lauretti B; Rocchi C; Simonelli I; Boffa L; Buttari F; Mercuri NB; Centonze D; Marfia GA
CNS Drugs; 2019 Nov; 33(11):1133-1139. PubMed ID: 31650471
[TBL] [Abstract][Full Text] [Related]
16. The expression pattern of VISTA in the PBMCs of relapsing-remitting multiple sclerosis patients: A single-cell RNA sequencing-based study.
Derakhshani A; Asadzadeh Z; Baradaran B; Safarpour H; Rahmani S; Leone P; Abdoli Shadbad M; Hosseinkhani N; Ghasemigol M; Ayromlou H; Ahmadi H; Pouya S; Shojaee M; Tabrizi NJ; Miraki Feriz A; Safarzadeh E; Racanelli V
Biomed Pharmacother; 2022 Apr; 148():112725. PubMed ID: 35183994
[TBL] [Abstract][Full Text] [Related]
17. Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis.
Guerriero C; Puliatti G; Di Marino T; Tata AM
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408975
[TBL] [Abstract][Full Text] [Related]
18. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
19. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
[TBL] [Abstract][Full Text] [Related]
20. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
